Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25377456 | 0.87 | MAPT (0.40) | MAPTLMNAHPGDHTTPDE10A | |
| SCHEMBL25379235 | 0.85 | CYP1A1 (0.37) | RAB9AMAPTNPSR1LMNAHPGD | |
| SCHEMBL25379789 | 0.83 | KDM4E (0.44) | — | |
| SCHEMBL25376091 | 0.83 | HTT (0.42) | NPBWR1RAB9AMAPTLMNAHPGD | |
| SCHEMBL25377856 | 0.83 | HAO1 (0.37) | MEN1KMT2ANPSR1PDE10A | |
| SCHEMBL25375008 | 0.82 | TRPV1 (0.34) | MAPTLMNAHPGDHTT | |
| SCHEMBL30482594 | 0.82 | TRPV1 (0.34) | MAPTLMNAHPGDHTT | |
| SCHEMBL25377412 | 0.82 | PDE10A (0.54) | AHRMAPTPDE10A | |
| SCHEMBL25379048 | 0.80 | LMNA (0.35) | NPBWR1LMNAHPGDHTTKDR | |
| SCHEMBL25379560 | 0.80 | TRPV1 (0.36) | MAPTLMNAHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146512-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146512-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |